Tvardi Therapeutics, Inc. Common Stock (TVRD)

Price$2.89

Growth ScoreD

Momentum ScoreF

Favorite Metrics

Price vs S&P 500 (26W)-37.78%

Price vs S&P 500 (4W)-30.85%

VGM Score23.94

Market Capitalization$27.11M

All Metrics

Book Value / Share (Quarterly)$1.55

P/TBV (Annual)1.96x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-32.30%

Cash Flow / Share (Quarterly)$-2.63

Price vs S&P 500 (YTD)-40.95%

Gross Margin (TTM)100.00%

Net Profit Margin (TTM)-503.21%

EPS (TTM)$-8.36

10-Day Avg Trading Volume0.06M

EPS Excl Extra (TTM)$-8.36

Revenue Growth (5Y)-18.54%

EPS (Annual)$-46.60

ROI (Annual)-125.86%

Gross Margin (Annual)91.31%

Net Profit Margin (5Y Avg)-428.07%

Cash / Share (Quarterly)$2.66

Revenue Growth QoQ (YoY)20.33%

ROA (Last FY)-201.33%

Revenue Growth TTM (YoY)-55.30%

EBITD / Share (TTM)$-4.41

ROE (5Y Avg)-70.79%

Operating Margin (TTM)-435.07%

Cash Flow / Share (Annual)$-2.50

P/B Ratio1.87x

P/B Ratio (Quarterly)2.06x

Net Income / Employee (Annual)$-5,905,600

Net Interest Coverage (TTM)-0.05x

ROA (TTM)-33.69%

EPS Incl Extra (Annual)$-46.60

Current Ratio (Annual)2.86x

Quick Ratio (Quarterly)2.22x

3-Month Avg Trading Volume0.05M

52-Week Price Return-88.20%

Revenue / Employee (TTM)$630,900

Tangible BV / Share (Quarterly)$1.51

P/S Ratio (Annual)3.80x

Asset Turnover (Annual)0.20x

52-Week High$43.65

Operating Margin (5Y Avg)-418.22%

EPS Excl Extra (Annual)$-46.60

CapEx CAGR (5Y)120.65%

26-Week Price Return-29.85%

Quick Ratio (Annual)2.79x

13-Week Price Return-28.11%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)2.25x

Enterprise Value$7.26M

Revenue / Share Growth (5Y)58.71%

Asset Turnover (TTM)0.15x

Revenue / Employee (Annual)$594,800

Inventory Turnover (Annual)0.33x

Pretax Margin (Annual)-998.53%

Cash / Share (Annual)$3.28

3-Month Return Std Dev77.25%

Net Income / Employee (TTM)$-1,162,100

ROE (Last FY)-207.61%

EPS Basic Excl Extra (Annual)$-46.60

Receivables Turnover (TTM)5.14x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-8.36

ROI (TTM)-4.47%

P/S Ratio (TTM)3.58x

Pretax Margin (5Y Avg)-429.29%

Revenue / Share (Annual)$4.69

Tangible BV / Share (Annual)$2.20

Price vs S&P 500 (52W)-112.57%

Year-to-Date Return-32.79%

5-Day Price Return-10.25%

EPS Normalized (Annual)$-46.60

ROA (5Y Avg)-75.02%

Net Profit Margin (Annual)-992.95%

Month-to-Date Return-14.50%

EBITD / Share (Annual)$-43.02

Operating Margin (Annual)-919.43%

LT Debt / Equity (Annual)0.65x

ROI (5Y Avg)-54.44%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-8.36

P/TBV (Quarterly)2.10x

P/B Ratio (Annual)1.93x

Inventory Turnover (TTM)0.00x

Pretax Margin (TTM)-508.47%

Book Value / Share (Annual)$2.23

Price vs S&P 500 (13W)-36.36%

Beta0.37x

P/FCF (Annual)9.61x

Revenue / Share (TTM)$4.97

ROE (TTM)-4.47%

52-Week Low$2.75

gGradeD

mGradeF

vgmGradeD

Show chart for

Earnings Surprise History

Q1 26-0.73est. -0.76

Analyst Recommendations

Mar 2026

Apr 2026

May 2026

Jun 2026

3.93

3.86

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
TVRDTvardi Therapeutics, Inc. Common Stock	—	D	F	$2.89
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Tvardi Therapeutics is a clinical-stage biopharmaceutical company developing oral small molecule therapies that target STAT3 for fibrosis-driven diseases. Its lead candidate, TTI-101, is in Phase 2 development for idiopathic pulmonary fibrosis and hepatocellular carcinoma. The company also has a second product candidate, TTI-109, designed to enhance STAT3 targeting.